Tonghua Dongbao Pharmaceutical (XSSC:600867) - Stock Price, News & Analysis

600867 Stock Overview

Researches and develops, manufactures, and sells pharmaceutical for the treatment of diabetes, endocrine, and cardiovascular and cerebrovascular diseases products in China. More details

600867 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	3/6

Rewards

Earnings are forecast to grow 69.66% per year

Analysts in good agreement that stock price will rise by 25.3%

Risk Analysis

Dividend of 3% is not well covered by earnings or free cash flows

Large one-off items impacting financial results

Profit margins (14%) are lower than last year (33.9%)

Tonghua Dongbao Pharmaceutical Co., Ltd. Competitors

Shanghai Shyndec Pharmaceutical

SHSE:600420

CN¥16.2b

Zhejiang Medicine

SHSE:600216

CN¥15.3b

Tianjin Chase Sun PharmaceuticalLtd

SZSE:300026

CN¥11.8b

Chengdu Kanghong Pharmaceutical Group

SZSE:002773

CN¥17.5b

Price History & Performance

Summary of all time highs, changes and price drops for Tonghua Dongbao Pharmaceutical
Historical stock prices
Current Share Price	CN¥8.34
52 Week High	CN¥12.28
52 Week Low	CN¥7.02
Beta	0.27
11 Month Change	-0.24%
3 Month Change	7.20%
1 Year Change	-31.47%
33 Year Change	-29.86%
5 Year Change	-37.15%
Change since IPO	-15.72%

Recent updates

Shareholder Returns

	600867	CN Pharmaceuticals	CN Market
7D	-3.0%	-1.5%	-2.1%
1Y	-31.5%	-9.4%	2.8%

Return vs Industry: 600867 underperformed the CN Pharmaceuticals industry which returned -9.4% over the past year.

Return vs Market: 600867 underperformed the CN Market which returned 2.8% over the past year.

Price Volatility

Is 600867's price volatile compared to industry and market?
600867 volatility
600867 Average Weekly Movement	5.7%
Pharmaceuticals Industry Average Movement	7.4%
Market Average Movement	8.4%
10% most volatile stocks in CN Market	12.7%
10% least volatile stocks in CN Market	5.7%

Stable Share Price: 600867 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 600867's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1985	3,196	Sheng Leng Chun	www.thdb.com

Tonghua Dongbao Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical for the treatment of diabetes, endocrine, and cardiovascular and cerebrovascular diseases products in China. The company operates through Pharmaceutical Industry; Building Materials Industry; and Real Estate Industry segments. It offers human insulin raw materials and injection, insulin glargine raw materials and injection, insulin aspart API and injection, Zhennaoning capsules, and diabetes-related medical devices.

Tonghua Dongbao Pharmaceutical Co., Ltd. Fundamentals Summary

How do Tonghua Dongbao Pharmaceutical's earnings and revenue compare to its market cap?
600867 fundamental statistics
Market cap	CN¥16.26b
Earnings (TTM)	CN¥341.31m
Revenue (TTM)	CN¥2.43b

47.6x

P/E Ratio

6.7x

P/S Ratio

Is 600867 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
600867 income statement (TTM)
Revenue	CN¥2.43b
Cost of Revenue	CN¥547.28m
Gross Profit	CN¥1.88b
Other Expenses	CN¥1.54b
Earnings	CN¥341.31m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.18
Gross Margin	77.49%
Net Profit Margin	14.04%
Debt/Equity Ratio	7.7%

How did 600867 perform over the long term?

See historical performance and comparison

Dividends

3.0%

Current Dividend Yield

157%

Payout Ratio

600867 Stock Overview

Rewards

Risk Analysis

Tonghua Dongbao Pharmaceutical Co., Ltd. Competitors

SHSE:600420

CN¥16.2b

SHSE:600216

CN¥15.3b

SZSE:300026

CN¥11.8b

SZSE:002773

CN¥17.5b

Price History & Performance

Recent News & Updates

New minor risk - Earnings quality

Third quarter 2024 earnings released: EPS: CN¥0.059 (vs CN¥0.14 in 3Q 2023)

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 16%

New minor risk - Profit margin trend

Now 21% overvalued

Recent updates

New minor risk - Earnings quality

Third quarter 2024 earnings released: EPS: CN¥0.059 (vs CN¥0.14 in 3Q 2023)

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 16%

New minor risk - Profit margin trend

Now 21% overvalued

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) announces an Equity Buyback for CNY 120 million worth of its shares.

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

First quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.13 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.79 in FY 2022)

Tonghua Dongbao Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.79 in FY 2022)

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 08, 2024

Adocia Announces its Partner Tonghua Dongbao Releases Positive Results on the Three Clinical Studies Conducted on BioChaperone Combo THDB0207 Formulation Containing Insulin Glargine and Insulin Lispro from Tonghua Dongbao

Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.18 in 2Q 2022)

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Full year 2022 earnings released: EPS: CN¥0.79 (vs CN¥0.64 in FY 2021)

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: CN¥0.80 (vs CN¥0.64 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.19 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 2Q 2021)

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) commences an Equity Buyback for CNY 360 million worth of its shares, under the authorization approved on March 25, 2022.

First quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥0.17 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.64 (vs CN¥0.46 in FY 2020)

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

An unknown buyer signed an agreement to acquire 5% stake in Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) from Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) for CNY 460 million.

Tonghua Dongbao Pharmaceutical Co., Ltd.(XSSC:600867) dropped from FTSE All-World Index (USD)

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 3Q 2020)

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) commences an Equity Buyback Plan for 24,000,000 shares, representing 1.18% for CNY 360 million, under the authorization approved on August 25, 2021.

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.13 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.46 (vs CN¥0.40 in FY 2019)

New 90-day low: CN¥11.82

Revenue misses expectations

Full year 2020 earnings released: EPS CN¥0.46

New 90-day low: CN¥12.87

New 90-day low: CN¥13.32

New 90-day high: CN¥14.91

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

Earnings released

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 20, 2020

Shareholder Returns

Price Volatility

About the Company

Tonghua Dongbao Pharmaceutical Co., Ltd. Fundamentals Summary

47.6x

6.7x

Earnings & Revenue

Dividends

3.0%

157%